# Effect of Evolocumab on Chronic Total Occlusions (EVOLO-CTO)

> **NCT05623995** · PHASE4 · UNKNOWN · sponsor: **Lin Zhao** · enrollment: 200 (estimated)

## Conditions studied

- In-stent Restenosis
- Major Adverse Cardiovascular Events

## Interventions

- **DRUG:** PCSK9 inhibitor
- **DRUG:** Statin

## Key facts

- **NCT ID:** NCT05623995
- **Lead sponsor:** Lin Zhao
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-15
- **Primary completion:** 2024-12-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05623995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05623995, "Effect of Evolocumab on Chronic Total Occlusions (EVOLO-CTO)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05623995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*